Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i>^<i>V600E</i> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.

ABSTRACT:

Purpose

Subprotocol H of the NCI-MATCH trial demonstrated the efficacy of dabrafenib + trametinib in a cohort of patients with BRAF^V600-mutated treatment-refractory solid tumors and myeloma. To confirm the longer-term efficacy and safety of this combination in additional patients, an expansion cohort was added.

Methods

Patients with BRAF^V600-mutated malignancies were eligible; patients with cholangiocarcinoma and low-grade serous ovarian cancer were excluded from the expansion cohort. Patients received dabrafenib 150 mg PO twice daily and trametinib 2 mg PO once daily. The primary end point was to evaluate the objective response rate (ORR); secondary end points included progression-free survival (PFS), 6-month PFS, and overal

SUBMITTER: Salama AKS 

PROVIDER: S-EPMC12810769 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature